Review



ctc  (RareCyte Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    RareCyte Inc ctc
    Ctc, supplied by RareCyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/ctc+analysis/nct05703399-19-3-3
    Average 90 stars, based on 1 article reviews
    ctc - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Immunofluorescence:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    Isolation:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    Staining:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    Biomarker Discovery:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    MANN-WHITNEY:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    Marker:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    Expressing:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    Membrane:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    In Situ:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.

    Selection:

    Article Title: Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types
    Article Snippet: However, the count of small CTCs (< 11.7 μm) was lower in the CTC-FIND method than in the RareCyte method ( e).

    Article Title: MC210301: Long Term Followup of Patients Enrolled in MC1137 (BEAUTY)
    Article Snippet: Measure Description: Using RareCyte CTC technology.



    Similar Products

    ctc  (MedChemExpress)
    94
    MedChemExpress ctc
    Ctc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/5-Cyano-2%2C3-di-(p-tolyl)tetrazolium+chloride/pm42075301-75-5-6
    Average 94 stars, based on 1 article reviews
    ctc - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    ctc procedures  (Streck Laboratories)
    98
    Streck Laboratories ctc procedures
    Ctc Procedures, supplied by Streck Laboratories, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/Cell-Free+DNA+BCT/pm41986320-147-5-13
    Average 98 stars, based on 1 article reviews
    ctc procedures - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    ctc  (RareCyte Inc)
    90
    RareCyte Inc ctc
    Ctc, supplied by RareCyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/ctc+analysis/nct05703399-19-3-3
    Average 90 stars, based on 1 article reviews
    ctc - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    primer smo l l mutant reverse ctc cag act gcc ttg gga aaa  (Jackson Laboratory)
    86
    Jackson Laboratory primer smo l l mutant reverse ctc cag act gcc ttg gga aaa
    Primer Smo L L Mutant Reverse Ctc Cag Act Gcc Ttg Gga Aaa, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/adipoq+cre+mice/pmc13122704-31-0-13
    Average 86 stars, based on 1 article reviews
    primer smo l l mutant reverse ctc cag act gcc ttg gga aaa - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    primer smo l l common forward gga ctc gca gga gga agc  (Jackson Laboratory)
    86
    Jackson Laboratory primer smo l l common forward gga ctc gca gga gga agc
    Primer Smo L L Common Forward Gga Ctc Gca Gga Gga Agc, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/genotyping+primers+standard/pmc13122704-29-0-12
    Average 86 stars, based on 1 article reviews
    primer smo l l common forward gga ctc gca gga gga agc - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ctc resin  (Iris Biotech Gmbh)
    86
    Iris Biotech Gmbh ctc resin
    Ctc Resin, supplied by Iris Biotech Gmbh, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/2+ctc+resin/pm42055239-168-0-14
    Average 86 stars, based on 1 article reviews
    ctc resin - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ctcs  (Menarini Silicon Biosystems)
    86
    Menarini Silicon Biosystems ctcs
    Clinical characteristics and CTC detection in patients with mBC. A Summary of the patients’ characteristics. Their mean age was 61.55 years (± 13.36) and most patients had HR + /HER2 − (83.3%, n = 50), followed by HR + /HER2 + (8.3%, n = 5), HR − /HER2 + (5.0%, n = 3), and triple-negative HR − /HER2 − cancer (3.3%, n = 2). First-line treatments included hormone therapy combined with CDK4/6 inhibitors, hormone therapy alone, chemotherapy alone, chemotherapy combined with targeted therapy, chemotherapy combined with immunotherapy, and other regimens. B Sankey diagram (left) showing the distribution of metastatic sites in the study cohort. The most frequent sites were bone, liver, lymph nodes and lung, followed by pleura, peritoneum, brain, pancreas, adrenal gland, skin and duodenum. Each line represents an individual patient. Histogram (right) showing the number of metastatic sites per patient. Most patients had one ( n = 26) or two ( n = 23) metastatic sites. C Schematic representation of CTC analysis in the 60 patients with mBC using <t>the</t> <t>CellSearch</t> ® platform: 35 were classified as CTC-positive (≥ 5 <t>CTCs/7.5</t> mL of blood), and 25 as CTC-negative. Representative images of CTCs identified by CellSearch ® . CTCs were defined as EpCAM + (based on the enrichment step), nucleated (DAPI⁺), cytokeratin-positive (CK⁺/FITC), and CD45⁻ (exclusion marker, APC) cells. Images show merged and individual fluorescence channels for both CTC-positive and CTC-negative samples
    Ctcs, supplied by Menarini Silicon Biosystems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/ctcs/pmc13154879-81-0-9
    Average 86 stars, based on 1 article reviews
    ctcs - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ctc count  (Menarini Silicon Biosystems)
    86
    Menarini Silicon Biosystems ctc count
    <t>CTC</t> <t>count</t> related to PFS and OS. CTC count < 5: blue line; CTC count ≥ 5: red line. ( A ) PFS in patients with positive ER expression by IHC; ( B ) OS in patients with positive ER expression by IHC. ( C ) PFS in patients with FES-PET positive result; ( D ) OS in patients with FES-PET positive result.
    Ctc Count, supplied by Menarini Silicon Biosystems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctc/count+ctc/pmc13114810-59-0-19
    Average 86 stars, based on 1 article reviews
    ctc count - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Clinical characteristics and CTC detection in patients with mBC. A Summary of the patients’ characteristics. Their mean age was 61.55 years (± 13.36) and most patients had HR + /HER2 − (83.3%, n = 50), followed by HR + /HER2 + (8.3%, n = 5), HR − /HER2 + (5.0%, n = 3), and triple-negative HR − /HER2 − cancer (3.3%, n = 2). First-line treatments included hormone therapy combined with CDK4/6 inhibitors, hormone therapy alone, chemotherapy alone, chemotherapy combined with targeted therapy, chemotherapy combined with immunotherapy, and other regimens. B Sankey diagram (left) showing the distribution of metastatic sites in the study cohort. The most frequent sites were bone, liver, lymph nodes and lung, followed by pleura, peritoneum, brain, pancreas, adrenal gland, skin and duodenum. Each line represents an individual patient. Histogram (right) showing the number of metastatic sites per patient. Most patients had one ( n = 26) or two ( n = 23) metastatic sites. C Schematic representation of CTC analysis in the 60 patients with mBC using the CellSearch ® platform: 35 were classified as CTC-positive (≥ 5 CTCs/7.5 mL of blood), and 25 as CTC-negative. Representative images of CTCs identified by CellSearch ® . CTCs were defined as EpCAM + (based on the enrichment step), nucleated (DAPI⁺), cytokeratin-positive (CK⁺/FITC), and CD45⁻ (exclusion marker, APC) cells. Images show merged and individual fluorescence channels for both CTC-positive and CTC-negative samples

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer

    doi: 10.1186/s13046-026-03709-3

    Figure Lengend Snippet: Clinical characteristics and CTC detection in patients with mBC. A Summary of the patients’ characteristics. Their mean age was 61.55 years (± 13.36) and most patients had HR + /HER2 − (83.3%, n = 50), followed by HR + /HER2 + (8.3%, n = 5), HR − /HER2 + (5.0%, n = 3), and triple-negative HR − /HER2 − cancer (3.3%, n = 2). First-line treatments included hormone therapy combined with CDK4/6 inhibitors, hormone therapy alone, chemotherapy alone, chemotherapy combined with targeted therapy, chemotherapy combined with immunotherapy, and other regimens. B Sankey diagram (left) showing the distribution of metastatic sites in the study cohort. The most frequent sites were bone, liver, lymph nodes and lung, followed by pleura, peritoneum, brain, pancreas, adrenal gland, skin and duodenum. Each line represents an individual patient. Histogram (right) showing the number of metastatic sites per patient. Most patients had one ( n = 26) or two ( n = 23) metastatic sites. C Schematic representation of CTC analysis in the 60 patients with mBC using the CellSearch ® platform: 35 were classified as CTC-positive (≥ 5 CTCs/7.5 mL of blood), and 25 as CTC-negative. Representative images of CTCs identified by CellSearch ® . CTCs were defined as EpCAM + (based on the enrichment step), nucleated (DAPI⁺), cytokeratin-positive (CK⁺/FITC), and CD45⁻ (exclusion marker, APC) cells. Images show merged and individual fluorescence channels for both CTC-positive and CTC-negative samples

    Article Snippet: CTCs were identified using the FDA-cleared CellSearch ® system (Menarini Silicon Biosystems, Inc., Bologna, Italy).

    Techniques: Marker, Fluorescence

    CTC count related to PFS and OS. CTC count < 5: blue line; CTC count ≥ 5: red line. ( A ) PFS in patients with positive ER expression by IHC; ( B ) OS in patients with positive ER expression by IHC. ( C ) PFS in patients with FES-PET positive result; ( D ) OS in patients with FES-PET positive result.

    Journal: Diagnostics

    Article Title: Circulating Tumor Cells Enhance Prognostic Stratification Beyond ER Assessment by Biopsy or FES-PET in Endocrine-Treated Metastatic Breast Cancer

    doi: 10.3390/diagnostics16081197

    Figure Lengend Snippet: CTC count related to PFS and OS. CTC count < 5: blue line; CTC count ≥ 5: red line. ( A ) PFS in patients with positive ER expression by IHC; ( B ) OS in patients with positive ER expression by IHC. ( C ) PFS in patients with FES-PET positive result; ( D ) OS in patients with FES-PET positive result.

    Article Snippet: CTC count was measured in 7.5 mL of CellSave blood within 96 h after collection, using the CellSearch System (Menarini-Silicon Biosystems).

    Techniques: Expressing